Verismo Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Philadelphia, Pennsylvania, United States
Type:
sample
Technology:
sample
sample
sample
sample
About: Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Verismo Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.